Ultrasound-Guided Rhomboid-Intercostal Block Versus Thoracic Paravertebral Block for VATS Analgesia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorGeorgios Kotsovolis

About this trial

Purpose of the study The goal of this research is to see which of two nerve-numbing techniques-the Rhomboid-Intercostal Block (RIB) or the Thoracic Paravertebral Block (PVB)-works better to control pain after chest surgery (specifically, video-assisted thoracoscopic surgery, or VATS). Both techniques use numbing medication to block pain signals after the operation.

Who can participate? The researchers are looking for adults between 18 and 85 years old who are scheduled for a specific type of chest surgery (a 3-port VATS procedure).

How will the research happen? Participants will be put into two equal groups by chance. One group will receive the RIB technique, and the other group will receive the PVB technique. Both procedures are done under ultrasound guidance after the completion of surgery, while the patient is still asleep. The pain levels of the participants will be measured at rest and when taking deep breaths at several times during the first 24 hours after surgery.

Why is this study useful? This study aims to find out which pain relief method is more effective and if one results in fewer side effects, such as nausea or the need for stronger pain medications (opioids). These results will possibly help doctors provide better comfort to patients recovering from chest surgery in the future.

Eligibility criteria

Qualifiers

Adults (18-85 years old),

ASA physical status I-III

scheduled for elective 3-port unilateral VATS.

Disqualifiers

Allergy to local anesthetics

infection at the injection site

coagulation disorders

severe neurological disorder

Trial design

Treatments tested in this trial

  • Ultrasound-Guided Rhomboid-Intercostal Block (RIB)
  • Ultrasound-Guided Thoracic Paravertebral Block (PVB)

Treatment groups

60 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Georgios Kotsovolis

Lead sponsor

Blue Cross of Thessaloniki

Sponsor institution